Drug Profile
Research programme: aptamer-based therapeutics - Archemix/Merck Serono
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Archemix Corporation; Merck Serono
- Class Oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 09 Apr 2009 Research is ongoing in Cancer in USA
- 17 Jan 2007 Early research in Cancer in USA (unspecified route)